Reference is made to the stock exchange announcement published on 26 October2022 by Lifecare AS (the "Company") announcing the successful completion of aprivate placement of new shares in the Company, with gross proceeds of NOK 45million (the "Private Placement"). The share capital increase related to the Private Placement has been registeredin the Norwegian Register of Business Enterprises, and the Company's newregistered share capital is NOK 47,146,296.80 divided into 117,865,742 shares,each with a par value of NOK 0.40.
For further information, please contact:
Joacim Holter, CEO, Lifecare AS, firstname.lastname@example.org, +47 40 05 90 40
This information is subject to the disclosure requirements pursuant to section5-12 of the Norwegian Securities Trading Act.This stock exchange announcementwas published by Joacim Holter, CEO at Lifecare AS, on 03.11.2022 at 21.58 CET.
This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturizedimplantable long-term sensor for correct and continuous monitoring of bloodsugar in people with diabetes. The Company's patented technology also has thepotential for use in various biomarkers. Lifecare AS is listed on EuronextGrowth (LIFE).